Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Nephritis | 5 | 2024 | 41 | 1.200 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2022 | 224 | 0.520 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2015 | 11 | 0.470 |
Why?
|
| Basement Membrane | 1 | 2015 | 40 | 0.450 |
Why?
|
| Autoantibodies | 1 | 2015 | 438 | 0.360 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 566 | 0.340 |
Why?
|
| Biomarkers | 2 | 2024 | 3400 | 0.340 |
Why?
|
| Renal Dialysis | 1 | 2015 | 949 | 0.270 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 436 | 0.230 |
Why?
|
| Microscopic Polyangiitis | 1 | 2024 | 14 | 0.220 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2024 | 26 | 0.220 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2024 | 39 | 0.220 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 942 | 0.210 |
Why?
|
| Rituximab | 1 | 2024 | 173 | 0.200 |
Why?
|
| Immunosuppressive Agents | 2 | 2024 | 658 | 0.200 |
Why?
|
| Remission Induction | 4 | 2024 | 301 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 2 | 2024 | 31 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 567 | 0.170 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2018 | 61 | 0.140 |
Why?
|
| Nephrotic Syndrome | 1 | 2018 | 53 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 731 | 0.140 |
Why?
|
| Kidney | 4 | 2024 | 1285 | 0.120 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2015 | 17 | 0.110 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2015 | 41 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 209 | 0.110 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 206 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 851 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 784 | 0.100 |
Why?
|
| Adolescent | 6 | 2024 | 20832 | 0.100 |
Why?
|
| Child | 7 | 2024 | 26214 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 790 | 0.090 |
Why?
|
| DNA | 1 | 2015 | 1413 | 0.080 |
Why?
|
| Female | 7 | 2024 | 70630 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3418 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4695 | 0.060 |
Why?
|
| Male | 6 | 2024 | 64680 | 0.060 |
Why?
|
| Humans | 8 | 2024 | 130776 | 0.060 |
Why?
|
| Complement C4 | 1 | 2024 | 5 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2024 | 26 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2024 | 54 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4664 | 0.050 |
Why?
|
| Complement C3 | 1 | 2024 | 43 | 0.050 |
Why?
|
| Proteinuria | 1 | 2024 | 106 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 597 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2023 | 61 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2024 | 15011 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12910 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17674 | 0.040 |
Why?
|
| Infant | 1 | 2015 | 13323 | 0.040 |
Why?
|
| Biopsy | 1 | 2022 | 1241 | 0.040 |
Why?
|
| Mice | 1 | 2015 | 18208 | 0.030 |
Why?
|
| Registries | 1 | 2024 | 1599 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5089 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1478 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 33891 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 6494 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 10021 | 0.010 |
Why?
|